anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
The invention comprises 5-aminoalkyl-5,7-dihydro - 6H - dibenzo[d,f][1,3]diazepin-6-one compounds of the formula &lt;FORM:0984092/C2/1&gt; and acid addition salts thereof; where n is 2 or 3; R represents a hydrogen atom or a methyl, ethyl or benzyl radical; R1 represents a methyl or ethyl radical; and R2 and R3 are the same and represent hydrogen or halogen atoms or methyl radicals. Compounds of the above formula where R is a methyl, ethyl or benzyl radical are prepared either by reacting an alkali metal salt of a compound of the formula &lt;FORM:0984092/C2/2&gt; with an aminoalkylhalide of the formula &lt;FORM:0984092/C2/3&gt; or, alternatively, by reacting a 2-amino-21-(aminoalkylamino -biphenyl compound of the formula &lt;FORM:0984092/C2/4&gt; with a reactive derivative of carbonic acid, e.g. urea, phosgene, ammonium carbamate or an alkali metal salt of cyanic acid; where R4 represents a methyl, ethyl or benzyl radical, X represents a halogen atom and n.  R1, R2 and R3 have the abovementioned significance. Compounds of Formula I in which R represents a hydrogen atom are prepared by hydrogenolysis of the corresponding benzyl compound.  Starting materials of formula II may be prepared by reacting a diaminobiphenyl compound of the formula &lt;FORM:0984092/C2/5&gt; with urea at a temperature between 180 DEG  C. and 210 DEG  C. until evolution of ammonia ceases. The alkali metal salts may be prepared by heating the dibenzo diazepinone compound with an alkali metal amide or hydride at the reflux temperature of the reaction solvent until salt formation is complete.  Starting materials of formula III may be prepared by reduction of biphenyl compounds of the formula &lt;FORM:0984092/C2/6&gt; which may in turn be prepared by the amino-alkylation of compounds of the formula &lt;FORM:0984092/C2/7&gt; or a N-formyl derivatives thereof with an aminoalkylhalide of the formula &lt;FORM:0984092/C2/8&gt; 2,21 - Diaminobiphenyl compounds of formula IV may be prepared by catalytic reduction of the corresponding 2,21-dinitrobiphenyl compounds.  2 - Nitro - 21 - aminobiphenyl compounds of formula VI may be prepared by selective reduction of the corresponding 2,21-dinitrobiphenyl compounds.  Pharmaceutical compositions for oral or parenteral administration comprise a compound of the invention together with a pharmaceutical diluent and/or excipient.  The compositions are active as central nervous system stimulants and diuretic agents and may be formulated as tablets, pills, sachets, packaged or encapsulated powders, solutions or suspensions.
Feedback systems and methods enhance obstructive and other obesity treatments by presenting feedback regarding patients&#39; actual eating and/or exercise habits. An ingestion restricting implant body can be deployed along the gastrointestinal tract. In some embodiments, ingestion alters the implant body, which, in turn, generates signals. The generated signals can be used to inhibit unhealthy ingestion by the patient. In other embodiments, the implant body can be altered by signals so as to selectable change the restriction imposed on the gastrointestinal tract, optionally in response to ingestion events, an eating schedule, or the like. The implant body may comprise a gastric band or an intragastric balloon. Sensor signals may be processed to identify ingestion and/or characterize ingestion of a solid or a liquid, and the results may be displayed on a screen for a patient or coach to view.
Methods are provided for the prognosis, diagnosis and treatment of various pathological states, including cancer, chemotherapy resistance and dementia associated with Alzheimer&#39;s disease. The methods provided herein are based on the discovery that various proteins with a high level of sialylation are shown herein to be associated with disease states, such as, cancer, chemotherapy resistance and dementia associated with Alzheimer&#39;s disease. Such methods provide a lysosomal exocytosis activity profile comprising one or more values representing lysosomal exocytosis activity. Also provided herein, is the discovery that low lysosomal sialidase activity is associated with various pathological states. Thus, the methods also provide a lysosomal sialidase activity profile, comprising one or more values representing lysosomal sialidase activity. A lysosomal sialidase activity profile is one example of a lysosomal exocytosis activity profile. As such, the level of lysosomal exocytosis activity and/or lysosomal sialidase activity is predictive of a diagnosis and/or prognosis of cancer, chemotherapy resistance or dementia associated with Alzheimer&#39;s disease.
PURPOSE:To produce the composite which is excellent in biological affinity and large in crushing resistance by mixing calcium hydrogen phosphate with calcium carbonate so that Ca and P are regulated to a specified molar ratio, pressurizing and molding the mixture and calcining the molded body in the specified conditions. CONSTITUTION:Ca source (calcium carbonate) and P source (calcium hydrogen phosphate) are mixed so that the molar ratio (Ca/P) of Ca and P is regulated to a range exceeding 1.77 and less than 2.00. The mixture is perssurized and molded. At this time, the particle diameter of a raw material is regulated to about 1-5mum and the pressing pressure is regulated to about 0.1-2.0t/cm&lt;2&gt;. Then this mixture is calcined at 1250-1600 deg.C for one hour or more and allowed to react and cooled. When it is cooled to about 1200 deg.C, it is maintained for about one hour and thereafter quenched at room temp. Thereby a tetracalcium phosphate composite contg. hydroxy-apatite excellent in biological affinity and crushing resistance. is obtained. This is preferable as medical application incorporating dental material.
The title of the invention of this disclosure is &#34;system and method for detecting or predicting major depressive disorder recurrence&#34;. The present invention provides a system and computer-implemented method for detecting depressive recurrence in a patient. The system includes a wearable device configured to detect movement of a patient and to generate body motion record data corresponding to the movement of the patient, and a computing device for retrieving the body motion record data from the device. The system and method obtains training data, including training actigraphy data, over a training period and trains an anomaly detector using the training data. The system and method then obtains test data from the patient, extracts a plurality of features from the test data, and analyzes the extracted data using a trained anomaly detector. A self-reporting test is used to determine whether an abnormality identified by the abnormality detector indicates that the patient is likely to experience a recurrence of depression.
PURPOSE: To produce finely powdered fibroin in high purity useful as cosmetic additive, by a method wherein scouring silk raw material is dissolved in a specified solvent, a coagulating salt is added to the resulting aq. soln. of silk fibroin, and the silk fibroin deposited is crushed.  
     CONSTITUTION: Scouring silk raw material is dissolved in at least one solvent selected from an aq. copper-ethylenediamine soln., an aq. copper hydroxide-ammonia soln. and an aq. LiBr soln. A coagulating salt such as NaCl or Na 2 SO 4  is added to a 5W20wt% of aq. silk fibroin soln. obtd. by dialysis in order to coagulate and deposit silk fibroin. Then the silk fibroin is dried at a temp. of 60W120°C and crushed and sized to a prticle diameter of 1W100μ to obtain finely powdered silk fibroin which has an average MW of not less than 50,000, is nonfibrous and has a bulk density of 0.1W0.7g/cm 3  in the dried state and in which molecular orientation is not more than half of that of natural fiber and not less than 50wt% of the fibroin is hot water-insoluble fibroin (β-structure). 
     COPYRIGHT: (C)1980,JPO&amp;Japio
A method of treatment of inflamed, pre-cancerous or cancerous tissue or polyps in a mammalian subject is disclosed. The treatment involves administration of a composition of at least one peptide agonist of a guanylate cyclase receptor and/or other small molecules that enhance intracellular production of cGMP. The at least one peptide agonist of a guanylate cyclase receptor may be administered either alone or in combination with an inhibitor of cGMP--dependent phosphodiesterase. The inhibitor may be a small molecule, peptide, protein or other compound that inhibits the degradation of cGMP. Without requiring a particular mechanism of action, this treatment may restore a healthy balance between proliferation and apoptosis in the subject&#39;s population of epithelial cells, and also suppress carcinogenesis.  Thus, the method may be used to treat, &lt;i&gt;inter alia&lt;i/&gt;, inflammation, including gastrointestinal inflammatory disorders, general organ inflammation and asthma, and carcinogenesis of the lung, gastrointestinal tract, bladder, testis, prostate and pancreas, or polyps.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a raw material for external use agent which utilizes a straining residue obtained by straining heated sweet potato.  &lt;P&gt;SOLUTION: The raw material for external use agent which utilizes a residue obtained by straining heated sweet potato, is provided. Also, an external use agent which uses the raw material for external use agent, is provided. The raw material for external use agent of this invention is easy to add to other base materials, contains a rich vegetable fiber, and furthermore, contains many functional components. Also, since it is high in processability, it can be utilized for various external use agents for these functionalities as purpose.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
This disclosure provides implantable devices with remote physiological monitoring capabilities. In particular, this disclosure relates to implantable devices with multi-spectral sensors that sense analyte from within a subject to provide clinically actionable data related to the subject&#39;s heath. For example, in preferred embodiments, the devices relate to ports with one or more multi-spectral sensors capable of remotely measuring symptoms of physiological distress via the multi-spectral sensors. In some embodiments, the ports are useful to deliver chemotherapy treatments and monitor patient health over the course of chemotherapy treatments. The multi-spectral sensors sense physical light properties modulated (e.g., reflected, absorbed, dispersed, scattered, etc.) by one or more analytes present in the body to allow for earlier detection of signs indicative of a health status.
23,022. Farbwerke vorm. Meister, Lucius, &amp; Br³ning. Oct. 19, 1910, [Convention date]. Toxines, anti-toxines, and like bacterial products. - To make tubercle-bacilli preparations, the bacilli are killed by drying in vacuo, and keeping a long time in desiccators protected from light. The bacilli which are cultivated on a nutrient broth such as glycerine, extract of meat, and peptone, are collected on a filter and washed with a sterilized salt solution. The bacilli are spread on flat glass dishes and placed in vacuum desiccators over concentrated sulphuric acid &amp;c. and remain there about a week until drv. The dried tubercle-bacilli are then kept in desiccators in flat open dishes protected from the action of light for several months or years, and are tested as to their power to develop by transferring small quantities to a nutrient medium and by testing their pathogenity for animals by inoculating guinea-pigs. When the above-described two tests give negative results the bacilli are suspended uniformly in a physiological salt solution without using any rough mechanical force which might destroy the bacilli.
PROBLEM TO BE SOLVED: To obtain the subject composition containing a cationic polymer and/or an amphoteric polymer and a specific lactam compound, and capable of retaining the conditioning effect for a long time. SOLUTION: The composition contains (A) 0.5-30wt.% of a compound of the formula [R&lt;1&gt; , R&lt;2&gt; are each H, a 1-8C alkyl, an alkenyl, an aryl, etc.; (n), (m) satisfy each the inequality: 2&lt;=(n)+(m)&lt;=4; etc.] and (B) 0.01-10wt.% of one or more kinds of polymers selected from a cationic polymer and an amphoteric polymer. The compound of the formula includes N-hexylpyrrolidone. The compound of the formula has a batter penetration-promoting action than those of benzyl alcohol or N-methyl or ethyl pyrrolidone which are conventional penetration-promoting agents. When hair is treated with the composition, the component A swells the hair, thereby promoting the penetration of the component B into the hair.  The composition can be used in the form of a hair pack, a hair dye, a hair treating agent, a styling agent, a permanent wave agent, a hair color, a hair-bleaching agent, a shampoo, a hair rinse, etc.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a new orally administrable DHEA (dehydroepiandrosterone) production promoter.  &lt;P&gt;SOLUTION: A composition comprising an extract from at least one plant selected from the group consisting of Rosaceae Crataegus, Saururaceae Houttuynia, Vitaceae Vitus and Compositae Anthermis (Chamaemelum) is provided as the DHEA production promoter. Any one kind or two or more kinds used in combination may be the extract. As a specific example, a mixture of the extract from the 4 species of plants is preferable. For example, the DHEA production promoter can be used as medicines such as an anti-aging agent which is a skin ameliorating agent etc., an immunopotentiator, an anti-diabetic agent, an anti-osteoporosis agent, anti-arteriosclerosis agent, an anti-obesity agent, a sleep promoter and an anti-central nervous system agent.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
Various of the disclosed embodiments provide Graphical User Interfaces (GUIs) for reviewing prior surgical procedures. Specifically, the GUI may allow a user, such as surgeon, to review sensor data, including video data, acquired during various of the surgeon&#39;s past surgical procedures. Some sensor data may be organized into metrics referred to herein as objective performance indicators (OPIs). Similarly, procedures may be discretized into specific tasks. By organizing and presenting data in OPI form at the task level, the GUI may facilitate efficient and coordinated review of the surgeon&#39;s progress over time across multiple procedures. In some embodiments, corresponding data from expert surgeons may also presented in the interface so that the user may gauge the surgeon&#39;s relative performance.
The present invention is directed to a high active sunscreen composition for topical application to human skin to protect the skin against UV radiation damage. The composition is particularly suitable for over-coating with make-up or other cosmetic compositions. More particularly, the present invention is directed to the use of a specific eutectic mixture of lower alkyl phthalamide that is surprisingly effective in solubilizing 4-(1,1-dimethylethyl)-4&#39;-methoxydibenzoylmethane (PARSOL.RTM. 1789). Such concentrates solutions of PARSOL.RTM. 1789 can be used to formulate a more effective sunscreen, having a surprisingly increased sunscreen protection factor (SPF) and such that the PARSOL.RTM. 1789 is more effective over a longer period of time so that the sunscreen composition need not be applied to the skin as frequently.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an automatic glycoprotein refining apparatus for automatically, aseptically, securely and efficiently refining a glycoprotein such as fibronectin etc. from blood plasma and a solution cartridge, a column cartridge and a flow path cartridge simply and securely used in the refining apparatus.  &lt;P&gt;SOLUTION: A blood plasma container 45 for accommodating the blood plasma, a first buffer solution container 44 filled with a first buffer solution, an eluate container 43 filled with an eluate and a second buffer solution container 42 filled with a second buffer solution are integrated into the solution cartridge 4. The solution cartridge 4 is mounted to a solution cartridge mount 21 of a cartridge mount 2 provided in a body 1. The column cartridge 5 is mounted to a column cartridge mount 22. The flow path cartridge 6 is mounted to a flow path cartridge mount 23.  &lt;P&gt;COPYRIGHT: (C)2004,JPO&amp;NCIPI
PROBLEM TO BE SOLVED: To obtain an apoptosis regulator useful for treating infectious diseases, immunopathy, malignant tumor, etc., by using a specific cinnamic acid derivative obtained from a natural extract, especially a propolis extract as an active ingredient. SOLUTION: This apoptosis regulator comprises a 3-[4-hydroxy-3,5-bis(3- methyl-2-butenyl)phenyl]-2-propenoic acid of the formula (X is a physiologically permissible cation) and/or its physiologically permissible salt (a salt such as Na, K, Ca or Mg is especially preferred) as an active ingredient. The compound is preferably derived from propolis. The active ingredient in an amount of preferably &gt;=0.01wt.% is contained in the apoptosis regulator. Since the active ingredient is readily oxidized, the use thereof together with an antioxidant usually blended in a food, a cosmetic or a medicine is preferred. The content of the antioxidant is preferably 0.01-10wt.%.
PURPOSE:To provide the subject remedy for trichophytosis composed of Japanese apricot pulp extraction, aloenin and an aqueous ethanol solution, free from side effects and capable of prolonged administration. CONSTITUTION:A remedy for trichophytosis containing 1.5-4.0 pts.wt., preferably 2.0-3.5 pts.wt. solid matter aloenin obtained by grinding and pressing a mixture composed of 100 pts.wt. 30% aqueous ethanol solution, 10-15 pts.wt., preferably 13-14 pts.wt. Japanese apricot pulp extract and naturally dried mesophyll of Aloe arborescens Mill., carrying out centrifugation and heating the resultant liquid material at &lt;=60 deg.C. Provided that citric acid is contained in an amount of 1.5 4.0 pts.wt. on sodium salt base in 10-15 pts.wt. Japanese apricot pulp extract. To the aloenin solid raw material, the Japanese apricot pulp extract and the aqueous ethanol solution are added and the resultant mixture is stirred using a mixer. The obtained liquid is allowed to stand at a cold and dark place and the supernatant is collected, thus preparing the objective remedy.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an esterified propolis excellent in digestive and absorptive properties and easily enhancing preferable physiological action of the propolis, and to provide a method for producing the same and to provide an anticancer agent and food formulation comprising the esterified propolis.  &lt;P&gt;SOLUTION: The esterified propolis is produced by esterifying an organic acid in the propolis by acting an enzyme to the propolis in the presence of an alcohol. A hydrolase such as a chlorogenic acid esterase, a tannase, a ferulic acid esterase, etc., is usable as the enzyme. The preferred propolis is an extract of propolis, more preferred is an alcohol extract of propolis, and most preferred is an ethanol extract of the propolis. The anticancer agent and food formulation comprises the esterified propolis.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide compounds for inactivating pathogens in materials.  &lt;P&gt;SOLUTION: Compounds and methods for inactivating pathogens in materials are described, including compositions and methods for inactivating pathogens in red blood cell preparations and biological materials such as plasma. The compounds and methods may be used to treat materials for in vitro or in vivo use, such as clinical testing or transfusion. The compounds are designed to specifically bind to and react with nucleic acid, and then to degrade to form degraded products. The degradation reaction is preferably slower than reactions with nucleic acid.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
PURPOSE:To obtain a kneaded gypsum material having excellent thixotropic properties, both excellent fluidity in vibration and packing properties in a gypsum composition consisting essentially of hemihydrate, by blending the gypsum composition with a specific amount of noncrystalline silica. CONSTITUTION:(A) 100 pts.wt. hemihydrate is blended with (B) 0.01-5 pts.wt. noncrystalline silica to give a gypsum composition. Powdery noncrystalline silica having &gt;=20m&lt;2&gt;/g specific surface area is preferable as the composition B. Since a kneaded gypsum material obtained by kneading the prepared gypsum composition with water has excellent thixotropic properties, the kneaded gypsum material can be completely cast into the fine parts of a negative mold when the kneaded gypsum material is poured into the negative mold while being vibrated. When vibration is suspended and the kneaded gypsum material is allowed to stand, the flow is stopped, the material can be packed and molded into a desired form and is suitably used as a material for manufacturing a pattern such as tooth mold especially in dental treatment.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a composition usable for the treatment or prevention of cranial nerve diseases, and the improvement in cerebral functions with little adverse effects, and highly safe even by administration over a long period of time.  &lt;P&gt;SOLUTION: The composition comprises an astringent skin of a peanut and/or an extract thereof as an active ingredient, and has one or more selected from among the group consisting of the treatment of the cranial nerve diseases, the prevention of the cranial nerve diseases, and the improvement in the cerebral functions as uses. One or more selected from among the group consisting of depression symptoms, anxiety symptoms, and dysmnesia are cited as the cranial nerve diseases. An improvement in a memorizing and learning ability is cited as the improvement in the cerebral functions. The composition can be prepared into any of foods, food additives, pharmaceuticals, feeds, and pet foods.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
PCT No. PCT/FR91/00055 Sec. 371 Date Jul. 31, 1992 Sec. 102(e) Date Jul. 31, 1992 PCT Filed Jan. 30, 1991 PCT Pub. No. WO91/11189 PCT Pub. Date Aug. 8, 1989.The present invention relates to the use of an  alpha -tocopherol phosphate, especially in its dl or d form, or an ester thereof, of the general formula    &lt;IMAGE&gt;  (I)  in which: R1 is a hydrogen atom, an alkyl radical having from 1 to 4 carbon atoms, such as the methyl or ethyl radical in particular, or an  alpha -tocopheryl radical; and R2 is a hydrogen atom, an alkyl radical having from 1 to 4 carbon atoms, such as a methyl or ethyl radical in particular, or an oxyethylene chain of the formula   &lt;IMAGE&gt;   in which R3 and R4 independently are a hydrogen atom or a methyl radical and n is an integer greater than or equal to 1, or a salt thereof, for preparing a pharmaceutical, dermatological or cosmetic composition for the prevention or treatment of allergic manifestations such as skin allergy or bronchial asthma, or inflammatory manifestations, or for the prevention or treatment of the harmful effects of free radicals.
The present invention is related to a novel compressed tablet composition for helping in giving birth to females. The composition is named &#34;Baby Love Female Tablets&#34;. The active ingredients comprised in the composition, according to the present invention, are selected according to two theories in modern medicine; thickness of the egg coat and cell fragility. The effectiveness of the novel drug depends on these two theories. The first theory proves that the egg coat differs in thickness from one woman to another; being the major factor in determining the sex of the baby. The second theory indicates the factors of strength, weakness and fragility of living cells in general and of corona radiata in particular. The present invention represents a medical breakthrough, which can help in choosing the sex of the baby and treating many incurable diseases.